Taxol for treating breast cancer
Executive Summary
FDA's Oncologic Drugs Advisory Committee will discuss Bristol- Myers Squibb's NDA (20-262) for Taxol (paclitaxel injection) for use after failure of first-line chemotherapy or subsequent chemotherapy for treatment of metastatic carcinoma of the breast during its Dec. 15 meeting. The committee also will review Burroughs Wellcome's NDA (20-388) for Navelbine (vinorelbine tartrate) for use as a single agent or in combination for treating unresectable advanced non-small cell lung cancer. The meeting begins at 8 a.m. in conference rooms D&E of FDAs Parklawn Building.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth